Treatment to restore low immune cells after cancer therapy
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial offers an investigational medicine (Nogapendekin-alfa Inbakicept) that may help raise your lymphocyte (white blood cell) levels, which often drop after cancer treatments. It is for people with solid tumors who have already tried standard therapies and whose immune systems are weak due to low lymphocyte counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor (not a blood cancer) that has progressed after at least one standard treatment.
- You currently have low lymphocytes (a type of white blood cell) or it is expected that your lymphocytes will drop by 20% or more soon.
- You do not have an uncontrolled autoimmune disease that requires immunosuppressive medication.
- You have not had a solid organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune-boosting therapy called NAI for people with sepsis who have persistently low lymphocyte counts (a sign of immune weakness). The goal is to see if it can help the immune system recover and improve recovery from sepsis. It is for patients already in the ICU on antibiotics.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This trial tests a combination of two medicines—thymalfasin and IL-2—to see if they can help raise low white blood cell counts (lymphocytes) in people with blood cancers. If you have low lymphocytes from your cancer or its treatment, this study may offer a way to boost your immune system.
Hear when a new Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.